4.5 Review

Wild type p53 reactivation: From lab bench to clinic

Journal

FEBS LETTERS
Volume 588, Issue 16, Pages 2628-2638

Publisher

WILEY
DOI: 10.1016/j.febslet.2014.03.049

Keywords

p53; Small molecule; Mdm2; MdmX; Apoptosis; ROS

Funding

  1. Swedish Research Council
  2. Swedish Cancer Society
  3. Ragner Soderberg
  4. Knut and Alice Wallenberg Foundations

Ask authors/readers for more resources

The p53 tumor suppressor is the most frequently inactivated gene in cancer. Several mouse models have demonstrated that the reconstitution of the p53 function suppresses the growth of established tumors. These facts, taken together, promote the idea of p53 reactivation as a strategy to combat cancer. This review will focus on recent advances in the development of small molecules which restore the function of wild type p53 by blocking its inhibitors Mdm2 and MdmX or their upstream regulators and discuss the impact of different p53 functions for tumor prevention and tumor eradication. Finally, the recent progress in p53 research will be analyzed concerning the role of p53 cofactors and cellular environment in the biological response upon p53 reactivation and how this can be applied in clinic. (C) 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available